Surgical robotics and procedure platforms are operating-room systems that combine surgeon consoles, robotic arms, instruments, imaging, navigation, implants, training, service contracts, leases, and hospital workflow software. They sit inside the procedure workflow, usually in hospital operating rooms or ambulatory surgical centers, where a surgeon uses a robot, navigation system, or enabling-technology platform to plan and perform a case. The economic path is installed systems and procedure volume first, then instrument use, accessories, service, leases, implant pull-through, upgrades, and training revenue. ISRG has the cleanest direct installed-base evidence, SYK is the second route through orthopedic robotics and enabling technology, and ZBH and MDT remain watch rows until robotics evidence is less dependent on broader medtech execution.
What the stack is: surgical robotics covers robot-assisted surgery platforms, orthopedic robotic arms, surgical navigation, procedure planning software, limited-life instruments, implant systems, service contracts, leasing programs, surgeon training, and hospital support.
What it does in robotics infrastructure: the stack turns a surgeon's procedure into repeatable motion control, visualization, planning, instrument use, implant positioning, operating-room data, service revenue, and follow-on system upgrades.
Main pieces: surgeon consoles, patient carts, robotic arms, endoscopes, staplers, biopsy tools, orthopedic cutting guides, implant kits, navigation cameras, preoperative planning software, service teams, sales reps, leases, and clinical training programs.
Where it sits: the hardware sits in hospital operating rooms, procedure suites, and ambulatory surgery centers; the economic record sits in installed base, procedure counts, instrument and accessory shipments, service contracts, lease assets, implant sales, and capital-equipment orders.
How the parent theme uses it: robotics adoption matters only when hospitals perform more robotic cases, use more consumables or implants per case, keep systems utilized, renew service, and accept upgrade or lease economics that become revenue, margin, cash flow, and guidance.
Terms used later: installed base means active placed systems; utilization means procedures per system; instrument pull-through means disposable or limited-use tool revenue tied to each case; attach means implant, service, software, or accessory revenue connected to a procedure; lease mix means systems placed through operating leases rather than upfront capital sales.
Report boundary: this is a tactical report-layer node. Durable company research, claim IDs, and raw source maintenance stay in the linked knowledge pages. Price and volume context comes from read-only discovery daily_ohlc through 2026-06-12; static setup thresholds in the metadata still come from the older 2026-05-29 package and must be refreshed before use as current trading evidence.
Current Setup
Procedure conversion gateRobotics pays when installed systems produce repeat cases and recurring revenue.
Hospitals have to keep systems utilized, instruments and service attached, and reimbursement or capital budgets stable enough for upgrades, leases, implants, and training to become cash flow.
Positive proofISRG has direct procedure and installed-base evidence.
Q1 2026 revenue grew 23%; da Vinci procedures rose about 16% and Ion procedures about 39%.
Conversion gateSYK needs Q2-H2 recovery after the cyber-hit quarter.
Mako and enabling technology matter if delayed sales, margin, and FY2026 guidance hold.
Primary constraintZBH and MDT still need robotics-specific proof.
Watch ZBH organic growth and MDT Hugo disclosure inside broader medtech margin and portfolio resets.
Demand sourceHospital and ASC cases
Installed baseSystems, arms, navigation
Revenue pathTools, service, implants
Proof pointMargins, FCF, guidance
Hospitals buy surgical robotics when the platform improves surgeon workflow, procedure capacity, implant pull-through, or case mix enough to support capital purchases, leases, service contracts, and instrument use. The economics are visible in placements, installed base, procedures per system, instruments and accessories, service revenue, implant or navigation attach, reimbursement, gross margin, free cash flow, and guidance. Right-rail charts now call the report API against local daily_ohlc through 2026-06-12, but static setup thresholds in this page's metadata still come from the older 2026-05-29 package.
The strongest operating evidence is still ISRG: the local lane and company release record Q1 2026 revenue growth of 23%, recurring revenue near 86% of revenue, da Vinci procedure growth near 16%, Ion procedure growth near 39%, 431 da Vinci placements, 52 Ion placements, and large da Vinci and Ion installed bases. SYK provides the second route because Mako and enabling technology sit inside orthopedic procedure workflows, with FY2026 guidance still calling for 8.0%-9.5% organic growth after a disrupted Q1. ZBH and MDT add robotics exposure through orthopedic and Hugo platforms, but their source sets require more separation between robotics adoption and broader medtech execution.
The node weakens if hospital capital budgets slow, reimbursement pressure hits procedure economics, system leases lower cash conversion, tariffs or service costs pressure gross margin, or competitive launches require price support. ZBH still needs organic growth, sales-force productivity, and Monogram milestones; MDT still needs Hugo adoption evidence inside a business where Cardiovascular, MiniMed, tariffs, margin bridge, and free cash flow dominate the latest local lane. Earnings dates for ZBH and MDT are not currently confirmed from a credible forward calendar in the bounded check.
Selected-security charts render through the right rail with /api/securities/<TICKER>/chart?frequency=weekly&window=3y&as_of=latest. Local discovery status checks on 2026-06-13 show 1,278 daily rows for each ticker from 2021-05-12 through 2026-06-12; lineage output still shows provider source_freshness of 2026-05-08 for the original daily_ohlc ingestion, so refresh setup levels before using chart thresholds as current trading evidence.
Basket
The ranked basket is hand-curated from the parent robotics theme, this node's existing metadata, linked knowledge lanes, company releases, and read-only discovery coverage. Ranking follows direct node economics first: ISRG is the purest recurring surgical-robotics platform, SYK is the direct orthopedic robotics and enabling-technology route, and ZBH and MDT remain watch rows because robotics is still mixed with broader orthopedic, cardiovascular, diabetes, tariff, margin, and portfolio evidence.
Pure-play installed-base robotics route with da Vinci and Ion procedure volume tied directly to instruments, accessories, systems, service, and leases.
Market cap$145.58B
Next earningsJul 21, 2026 est.
Latest qtr revenue$2.7708B
Role in stack
ISRG sells and leases da Vinci surgical systems and Ion lung-biopsy systems to hospitals, then monetizes utilization through instruments, accessories, service, training, and upgrades. Procedure volume is the conversion gate because each robotic case can pull consumables and service through the installed base.
Revenue mix
Q1 2026 revenue was led by instruments and accessories at $1.6864B, with systems at $650.7M and service at $433.7M. Recurring revenue was about 86% of total revenue in the local lane.
Latest qtr revenue
Q1 2026 total revenue was $2.7708B for the quarter ended March 31, 2026, from Intuitive's April 21, 2026 first-quarter release. The same release reported about 16% da Vinci procedure growth and about 39% Ion procedure growth.
Orthopedic robotics route where Mako, enabling technology, implants, instruments, and procedure recovery have to validate the maintained FY2026 guide.
Market cap$119.69B
Next earningsJul 30, 2026 est.
Latest qtr revenue$6.020B
Role in stack
SYK sells orthopedic implants, Mako robotic workflow, Ortho Tech, surgical instruments, and MedSurg technology into hospital and procedure channels. Robotics converts when orthopedic cases, implant pull-through, enabling technology, and delayed Q1 sales recovery support organic growth, margin, and cash flow.
Revenue mix
Q1 2026 net sales were $3.207B in MedSurg and Neurotechnology and $2.813B in Orthopaedics. Ortho Tech includes Mako and enabling technologies after the 2026 reporting change.
Latest qtr revenue
Q1 2026 net sales were $6.020B for the quarter ended March 31, 2026, from Stryker's April 30, 2026 release. Management maintained FY2026 organic growth guidance of 8.0%-9.5% after the cyber-disrupted quarter.
Orthopedic robotics watch row where ROSA, TMINI, Monogram, knees, hips, and sales-force execution still need cleaner organic growth proof.
Market cap$17.13B
Next earningsNot confirmed
Latest qtr revenue$2.087B
Role in stack
ZBH sells orthopedic implants and procedure technology, including ROSA, TMINI, surgical planning tools, knees, hips, and later Monogram robotics. The conversion gate is whether robotics and sales-channel changes lift organic growth and procedure share rather than only adding acquisition-aided reported growth.
Revenue mix
The local ZBH lane frames the company around reconstructive orthopedics: 2025 revenue was led by knees, hips, S.E.T., and Technology & Data/Bone Cement/Surgical. Q1 2026 Americas remained the largest reporting segment.
Latest qtr revenue
Q1 2026 sales were $2.087B for the quarter ended March 31, 2026, from the linked ZBH lane's Q1 2026 release and 10-Q routing. The bounded web calendar check did not confirm a forward earnings date, so the card does not estimate one.
Diversified medtech watch row where Hugo robotics must become visible inside a larger Cardiovascular, Medical Surgical, MiniMed, tariff, and margin bridge.
Market cap$102.97B
Next earningsNot confirmed
Latest qtr revenue$9.81B
Role in stack
MDT sells device platforms across Cardiovascular, Neuroscience, Medical Surgical, and related procedure channels, with Hugo as the surgical-robotics route. Hugo converts for this node only if clearance, placements, trained surgeons, procedure volume, service attach, and disclosed economics become visible inside the broader company.
Revenue mix
Fiscal Q4 2026 was led by Cardiovascular at about $3.8B, with Neuroscience near $2.75B and Medical Surgical near $2.39B in the public release coverage. Robotics remains a smaller proof item within Medical Surgical rather than the enterprise growth engine.
Latest qtr revenue
Fiscal Q4 2026 net sales were $9.81B for the quarter ended April 24, 2026, from Medtronic's June 3, 2026 release. The same update was past-dated relative to this page refresh, and no credible forward fiscal Q1 2027 date was confirmed in the bounded check.
Market caps use StockAnalysis close-of-market snapshots from June 12, 2026. ISRG and SYK next earnings dates come from StockAnalysis and are labeled estimated. ZBH and MDT had no credible confirmed forward date in the bounded check: StockAnalysis showed ZBH's already-reported April 28, 2026 date and MDT's already-reported June 3, 2026 date, so both cards use Not confirmed.
What Confirms Or Weakens
AreaWhat confirmsWhat weakens or invalidatesWatch next
01Node thesisProcedures become recurring economics
What confirms
Procedure volume, placements, installed base, instrument pull-through, service revenue, margin, free cash flow, and guidance improve together.
What weakens or invalidates
System placements rise without utilization, consumables, service margin, reimbursement support, or cash conversion.
Watch next
Procedures per system
Service margin
Lease mix
Hospital capital comments
02Economics mechanismRevenue converts to margin and cash
What confirms
Instrument and accessory revenue, service attach, implant pull-through, product gross margin, operating cash flow, and guidance move with installed-base growth.
What weakens or invalidates
Tariffs, service costs, operating leases, working capital, acquisition spending, or launch costs absorb the reported procedure and revenue gains.
Watch next
ISRG gross margin
SYK adjusted margin
ZBH FCF
MDT GAAP bridge
03CustomerHospital budget and adoption
What confirms
Hospitals keep buying or leasing systems, trained surgeons add cases, ASCs adopt where economics work, and reimbursement supports procedure activity.
What weakens or invalidates
Hospital capex tightens, reimbursement pressure slows cases, new systems sit underused, or competitors force price support without utilization gains.
Watch next
Capital-budget commentary
Procedure categories
OUS demand
China pricing
04FundingCash supports installed base
What confirms
Operating cash flow covers inventory, lease assets, service support, manufacturing expansion, debt service, integration, and platform upgrades without weakening guidance.
What weakens or invalidates
Working capital, lease assets, debt, acquisition integration, or buybacks consume cash faster than robotics and procedure growth can replenish it.
Watch next
ISRG lease assets
SYK debt and cash
ZBH maturities
MDT FCF
05Policy and operating constraintReimbursement, tariff, and product proof
What confirms
Reimbursement remains stable, tariffs are bridged, product clearances become placements, and safety or recall issues do not interrupt procedure adoption.
What weakens or invalidates
Reimbursement pressure, tariffs, service costs, product issues, competitive systems, or regulatory delays reduce procedure economics or upgrade demand.
Watch next
FY2026 tariff bridges
Hugo clearance and use
Monogram timing
FDA/product notices
06Stale conditionChart and source refresh
What confirms
Discovery rows, API charts, setup labels, earnings releases, and linked security lanes are refreshed together after market data or operating events.
What weakens or invalidates
Static setup thresholds from 2026-05-29 are used as current evidence after 2026-06-12 daily bars, new earnings dates, or new operating releases arrive.
Watch next
Weekly OHLC recompute
Security-lane refresh
Earnings calendar refresh
Lineage update
Source Trail
Route
Use it for
Primary links
Parent Robotics map
Value-chain placement, return basket, and route back to the node header.
Read-only local price coverage, status and lineage checks, API chart routing, weekly OHLC assumptions, and stale setup caveats.
node report.json; query refs are discovery:status:ISRG|SYK|ZBH|MDT:2026-06-13, discovery:lineage-status:daily_ohlc:ISRG|SYK|ZBH|MDT:2026-06-13, discovery:duckdb:daily_ohlc_coverage:ISRG|SYK|ZBH|MDT:2026-06-12, and right-rail API route /api/securities/<TICKER>/chart?frequency=weekly&window=3y&as_of=latest. Charts should use daily_ohlc, weekly aggregation by calendar week, a three-year visible horizon, 20-week EMA, 100-week EMA, and volume; static setup levels remain stale from the 2026-05-29 package.